An adult woman with Dravet syndrome (documented SCN1A mutation) experienced a marked reduction in seizures when treated with the selective serotonin reuptake inhibitor (SSRI) fluoxetine. The seizure reduction may be partly due to reductions associated with aging in patients with Dravet syndrome, but it appears to be due, at least in part, to fluoxetine. A prior preliminary study reported that fenfluramine reduces seizures in patients with Dravet syndrome. Fenfluramine may produce this effect by increasing serotonin brain levels, and SSRIs have been found to possess antiepileptic properties in animal models of epilepsy. Given the known cardiac risks of fenfluramine, randomized clinical trials with SSRIs should be considered in Dravet syndrom...
We report on a patient who developed, from 5 months of age, multiple seizure types, including myoclo...
Purpose: Dravet syndrome (DS) is a rare epilepsy with seizures’ onset during the first year of life...
Dravet syndrome (DS), or severe myoclonic epilepsy in infancy, is one of the most severe types of ge...
AbstractAn adult woman with Dravet syndrome (documented SCN1A mutation) experienced a marked reducti...
A 20-year-old woman with Dravet syndrome and multiple prior episodes of status epilepticus presented...
Dravet syndrome (DS) is a severe, drug-resistant epilepsy. Fenfluramine has been reported to have a ...
Background: Dravet syndrome is a rare, treatment-resistant developmental epileptic encephalopathy ch...
In this paper, we review the experience with fenfluramine in epileptic and other paroxysmal disorder...
Importance: Fenfluramine treatment may reduce monthly convulsive seizure frequency in patients with ...
Dravet syndrome, a severe infantile epilepsy syndrome, is typically resistant to anti-epileptic drug...
Dravet syndrome is an epilepsy syndrome of infantile onset, frequently caused by SCN1A mutations or ...
Abstract Anti‐seizure medications that block sodium channels are generally considered contraindicate...
In 2020, racemic-fenfluramine was approved in the U.S. and Europe for the treatment of seizures asso...
Dravet syndrome (DS) is one of the most pharmacoresistant and devastating forms of childhood epileps...
We report on a patient who developed, from 5 months of age, multiple seizure types, including myoclo...
We report on a patient who developed, from 5 months of age, multiple seizure types, including myoclo...
Purpose: Dravet syndrome (DS) is a rare epilepsy with seizures’ onset during the first year of life...
Dravet syndrome (DS), or severe myoclonic epilepsy in infancy, is one of the most severe types of ge...
AbstractAn adult woman with Dravet syndrome (documented SCN1A mutation) experienced a marked reducti...
A 20-year-old woman with Dravet syndrome and multiple prior episodes of status epilepticus presented...
Dravet syndrome (DS) is a severe, drug-resistant epilepsy. Fenfluramine has been reported to have a ...
Background: Dravet syndrome is a rare, treatment-resistant developmental epileptic encephalopathy ch...
In this paper, we review the experience with fenfluramine in epileptic and other paroxysmal disorder...
Importance: Fenfluramine treatment may reduce monthly convulsive seizure frequency in patients with ...
Dravet syndrome, a severe infantile epilepsy syndrome, is typically resistant to anti-epileptic drug...
Dravet syndrome is an epilepsy syndrome of infantile onset, frequently caused by SCN1A mutations or ...
Abstract Anti‐seizure medications that block sodium channels are generally considered contraindicate...
In 2020, racemic-fenfluramine was approved in the U.S. and Europe for the treatment of seizures asso...
Dravet syndrome (DS) is one of the most pharmacoresistant and devastating forms of childhood epileps...
We report on a patient who developed, from 5 months of age, multiple seizure types, including myoclo...
We report on a patient who developed, from 5 months of age, multiple seizure types, including myoclo...
Purpose: Dravet syndrome (DS) is a rare epilepsy with seizures’ onset during the first year of life...
Dravet syndrome (DS), or severe myoclonic epilepsy in infancy, is one of the most severe types of ge...